Literature DB >> 25015302

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.

Kelly L Stoner1, Helena Harder, Lesley J Fallowfield, Valerie A Jenkins.   

Abstract

BACKGROUND: Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer.
METHODS: A systematic review was conducted by searching seven electronic databases for articles published up to February 2014. Included studies were randomized controlled trials (RCTs) and/or crossover designs investigating patient preference for SC versus IV administration. The risk of bias in the RCTs was determined using the Cochrane Collaboration tool. Reviewers independently extracted data and assessed the risk of bias. Any discrepancies were resolved by consensus.
RESULTS: The search identified 115 publications, but few (6/115) met the inclusion criteria. Patient populations and drugs investigated were diverse. Four of six studies demonstrated a clear patient preference for SC administration. Main factors associated with SC preference were time saving and the ability to have treatment at home. Only three studies used study-specific instruments to measure preference.
CONCLUSIONS: Results suggest that patients prefer SC over IV delivery. Patient preference has clearly been neglected in clinical research, but it is important in medical decision making when choosing treatment methods as it has implications for adherence and quality of life. If the safety and efficacy of both administration routes are equivalent, then the most important factor should be patient preference as this will ensure optimal treatment adherence and ultimately improve patient experience or satisfaction. Future drug efficacy and safety studies should include contemporaneous, actual patient preference where possible, utilizing appropriate measures.

Entities:  

Year:  2014        PMID: 25015302     DOI: 10.1007/s40271-014-0075-y

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  34 in total

1.  Patient preferences in choosing anti-TNF therapies-R1.

Authors:  E L Williams; C J Edwards
Journal:  Rheumatology (Oxford)       Date:  2006-11-03       Impact factor: 7.580

Review 2.  Why I use subcutaneous immunoglobulin (SCIG).

Authors:  Ralph S Shapiro
Journal:  J Clin Immunol       Date:  2012-12-21       Impact factor: 8.317

Review 3.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

4.  Patient-controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone.

Authors:  M L Urquhart; K Klapp; P F White
Journal:  Anesthesiology       Date:  1988-09       Impact factor: 7.892

5.  Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

Authors:  T Harbo; H Andersen; A Hess; K Hansen; S H Sindrup; J Jakobsen
Journal:  Eur J Neurol       Date:  2009-02-19       Impact factor: 6.089

6.  Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.

Authors:  Anatole Besarab; Carolina M Reyes; John Hornberger
Journal:  Am J Kidney Dis       Date:  2002-09       Impact factor: 8.860

7.  Rapid vascular glucose uptake via enzyme-assisted subcutaneous infusion: enzyme-assisted subcutaneous infusion access study.

Authors:  Olanrewaju A Soremekun; Melissa L Shear; Sagar Patel; Gina J Kim; Paul D Biddinger; Blair A Parry; Maria A Yialamas; Stephen H Thomas
Journal:  Am J Emerg Med       Date:  2009-11       Impact factor: 2.469

8.  How do patients with inflammatory bowel disease want their biological therapy administered?

Authors:  Patrick B Allen; Hannah Lindsay; Tony C K Tham
Journal:  BMC Gastroenterol       Date:  2010-01-10       Impact factor: 3.067

9.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more
  26 in total

1.  Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies.

Authors:  Chaitanya Sudrik; Theresa Cloutier; Phuong Pham; Hardeep S Samra; Bernhardt L Trout
Journal:  MAbs       Date:  2017-07-31       Impact factor: 5.857

2.  Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.

Authors:  Johnny Mahlangu; Howard Levy; Marina V Kosinova; Heghine Khachatryan; Bartosz Korczowski; Levani Makhaldiani; Genadi Iosava; Martin Lee; Frank Del Greco
Journal:  Res Pract Thromb Haemost       Date:  2021-08-17

Review 3.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

4.  Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma.

Authors:  Gary T Ferguson; Adel H Mansur; Joshua S Jacobs; Jacques Hebert; Corbin Clawson; Wenli Tao; Yanping Wu; Mitchell Goldman
Journal:  J Asthma Allergy       Date:  2018-04-05

5.  Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Authors:  Timo Purmonen; Kari Puolakka; Devarshi Bhattacharyya; Minal Jain; Janne Martikainen
Journal:  Cost Eff Resour Alloc       Date:  2018-11-16

6.  A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Authors:  A Doria; D Bass; A Schwarting; A Hammer; D Gordon; M Scheinberg; N L Fox; J Groark; W Stohl; C Kleoudis; D Roth
Journal:  Lupus       Date:  2018-05-28       Impact factor: 2.911

7.  Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects.

Authors:  Wendy D Woodley; Wen Yue; Didier R Morel; Audrey Lainesse; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-03-25       Impact factor: 4.689

8.  Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Authors:  Karissa Johnston; Jayson M Stoffman; Alexis T Mickle; Robert J Klaassen; Demitri Diles; Shade Olatunde; Lina Eliasson; Roxana Bahar
Journal:  Patient Prefer Adherence       Date:  2021-06-24       Impact factor: 2.711

Review 9.  Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.

Authors:  Stanley Cohan
Journal:  Biologics       Date:  2016-09-12

10.  Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.

Authors:  Raj Tummala; Tomas Rouse; Anna Berglind; Linda Santiago
Journal:  Lupus Sci Med       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.